Sengenics to Launch Global Biomarker Discovery and Clinical Trials Service Based on Oxford Gene Technology’s Patented Functional Protein Array

Sengenics today announced that it has signed an agreement with Oxford Gene Technology (OGT) to enable the launch of a global cancer biomarker discovery and clinical trial immuno-response monitoring service. The service will be based upon OGT’s proprietary full-length functional protein array platform. Sengenics has been offering protein array-based biomarker discovery services through OGT for a number of years. The [PR.com]
PR.com Press Releases: Medical & Health: Pharmaceuticals News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us